Between 2021 and 2022, Speyside partnered with a healthcare company in Brazil to analyze stakeholder discussions on CAR-T cell therapy and provide strategic recommendations for its future inclusion in the public health system (SUS). The project involved a literature review, legal and institutional analysis, and interviews with ten key stakeholders. This work resulted in nine strategic action areas, with specific short-, medium-, and long-term recommendations, including a multistakeholder workshop to address bottlenecks in oncologic care.

Between 2021 and 2022, Speyside worked in partnership with a healthcare company in Brazil. The objective of the project was to capture, in depth, the discussions held by different stakeholder groups about CAR-T cell therapy in Brazil.

Based on this, our consultancy developed recommendations to support the company in the decision-making process about the optimal strategies for future availability of the therapy in the public health system (SUS).

Speyside started with a literature review of academic articles and journals, case studies, institutional documents and legal framework to understand the scenario around advanced therapies in Brazil.

In a second moment, we mapped and interviewed ten key stakeholders for the theme (managers, clinicians, PAGs, researchers, and HTA specialists), based on pre-selected questions.

With these inputs, Speyside delimited nine central axes of action for Janssen in the upcoming years, regarding CAR-T cell therapy.

For each of the axes, specific actions were recommended to the company to ensure, in the medium and long term, the availability of the product in SUS.

One of them, was to hold a multistakeholder workshop to discuss solutions to the bottlenecks of oncologic care in the country.